Scientists at the University of Liverpool have demonstrated that a drug for treating hepatitis B virus (HBV) could be mass-produced for only £24 ($36) per person per year, versus the current UK NHS price of £4,600, and ...
Apr 22, 2015
0
23
(HealthDay)—In patients with type 2 diabetes and nephropathy, a lower creatinine excretion rate (CER) is associated with higher all-cause mortality, according to research published online Jan. 8 in Diabetes Care.
Feb 12, 2013
0
0
An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.
Jun 4, 2012
0
0
The U.S. Food and Drug Administration has approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of patients with neurotrophic tyrosine receptor kinase (NTRK)-positive locally ...
Jun 21, 2024
0
0
US pharmaceutical company Bristol Myers Squibb announced a $4.8 billion deal on Sunday to acquire cancer drugmaker Mirati Therapeutics.
Oct 9, 2023
0
1
Patients with advanced lung cancer had a better chance at survival when their treatment combined chemotherapy with a drug designed to turn the immune system against cancer, according to two studies released Sunday at a conference ...
Sep 12, 2022
0
9
Determining the optimal treatment sequence for patients with BRAF V600 mutant metastatic melanoma was the focus of the DREAMseq phase 3 clinical trial. The combination of nivolumab and ipilimumab (N/I), followed by the combination ...
Nov 16, 2021
0
1
A Hawaii court ordered Bristol-Myers Squibb and Sanofi to pay the state $834 million over marketing claims for blood thinner, Plavix, according to news reports.
Feb 16, 2021
0
3
The U.S. Food and Drug Administration has approved ozanimod, an immune-modulating therapy invented at Scripps Research, for the treatment of adults with relapsing forms of multiple sclerosis. The drug is also in advanced ...
Mar 26, 2020
0
5
Amgen has agreed to acquire the global rights to Otezla, a drug used for the treatment of psoriasis and psoriatic arthritis, for $13.4 billion in cash, Bristol Myers Squibb said Monday.
Aug 26, 2019
0
2
